Tripathi SK - Search Results

1

Phytomedicines Targeting Cancer Stem Cells: Therapeutic Opportunities and Prospects for Pharmaceutical Development.

Gupta PK, Saraff M, Gahtori R, Negi N, Tripathi SK, Kumar J, Kumar S, Aldhayan SH, Dhanasekaran S, Abomughaid MM, Dua K, Gundamaraju R, Ojha S, Ruokolainen J, Jha NK, Kesari KK. Gupta PK, et al. Among authors: tripathi sk. Pharmaceuticals (Basel). 2021 Jul 15;14(7):676. doi: 10.3390/ph14070676. Pharmaceuticals (Basel). 2021. PMID: 34358102 Free PMC article. Review.

2

Metal-free semi-aromatic polyester as nanodrug carrier: A novel tumor targeting drug delivery vehicle for potential clinical application.

Gupta PK, Tripathi SK, Pappuru S, Chabattula SC, Govarthanan K, Gupta S, Biswal BK, Chakraborty D, Verma RS. Gupta PK, et al. Among authors: tripathi sk. Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110285. doi: 10.1016/j.msec.2019.110285. Epub 2019 Oct 8. Mater Sci Eng C Mater Biol Appl. 2020. PMID: 31761245

3

Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy.

Tripathi SK, Panda M, Biswal BK. Tripathi SK, et al. Food Chem Toxicol. 2019 Mar;125:566-582. doi: 10.1016/j.fct.2019.01.018. Epub 2019 Jan 24. Food Chem Toxicol. 2019. PMID: 30685472 Review.

4

SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.

Tripathi SK, Biswal BK. Tripathi SK, et al. Life Sci. 2021 Jul 15;277:119608. doi: 10.1016/j.lfs.2021.119608. Epub 2021 May 11. Life Sci. 2021. PMID: 33989664

5

Plumbagin engenders apoptosis in lung cancer cells via caspase-9 activation and targeting mitochondrial-mediated ROS induction.

Tripathi SK, Rengasamy KRR, Biswal BK. Tripathi SK, et al. Arch Pharm Res. 2020 Feb;43(2):242-256. doi: 10.1007/s12272-020-01221-6. Epub 2020 Feb 7. Arch Pharm Res. 2020. PMID: 32034669

6

SOX9: An emerging driving factor from cancer progression to drug resistance.

Panda M, Tripathi SK, Biswal BK. Panda M, et al. Among authors: tripathi sk. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188517. doi: 10.1016/j.bbcan.2021.188517. Epub 2021 Jan 29. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33524528 Review.

7

SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance.

Tripathi SK, Sahoo RK, Biswal BK. Tripathi SK, et al. Drug Discov Today. 2022 Sep;27(9):2541-2550. doi: 10.1016/j.drudis.2022.05.022. Epub 2022 May 27. Drug Discov Today. 2022. PMID: 35636723 Review.

8

Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers.

Panda M, Tripathi SK, Zengin G, Biswal BK. Panda M, et al. Among authors: tripathi sk. Cell Biol Toxicol. 2023 Feb;39(1):1-31. doi: 10.1007/s10565-022-09772-8. Epub 2022 Sep 23. Cell Biol Toxicol. 2023. PMID: 36138312 Review.

9

Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer.

Biswal S, Panda M, Sahoo RK, Tripathi SK, Biswal BK. Biswal S, et al. Among authors: tripathi sk. Arch Oral Biol. 2023 Jul;151:105697. doi: 10.1016/j.archoralbio.2023.105697. Epub 2023 Apr 13. Arch Oral Biol. 2023. PMID: 37079976 Review.

10

Exposure of piperlongumine attenuates stemness and epithelial to mesenchymal transition phenotype with more potent anti-metastatic activity in SOX9 deficient human lung cancer cells.

Tripathi SK, Sahoo RK, Biswal BK. Tripathi SK, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan 27. doi: 10.1007/s00210-024-02965-4. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38280008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page